Opexa Therapeutics (OPXA), a biopharmaceutical company, develops personalized cellular therapies to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its leading therapy candidate includes Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. OPXA was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics in June 2006 < founded in 2003> and is based in The Woodlands, Texas.
September 1, 2017
RegMed Investors’ (RMi) closing bell; cell and gene therapy equities are slow movers or down
August 31, 2017
RegMed Investors’ (RMi) closing bell; the sector was rising
August 30, 2017
RegMed Investors’ (RMi) closing bell; Novartis (NVS) moves today’s sector
August 29, 2017
RegMed Investors’ (RMi) closing bell; buying opportunities?
August 28, 2017
RegMed Investors’ (RMi) closing bell; Gilead (GILD) makes a timely, expensive and plucky deal to diversify
August 24, 2017
RegMed Investors’ (RMi) closing bell; here we go again…
August 23, 2017
RegMed Investors’ (RMi) closing bell; sector was up
August 22, 2017
RegMed Investors’ (RMi) closing bell; today’s bounce back sector is …
August 21, 2017
RegMed Investors’ (RMi) closing bell; sector takes another dive
August 9, 2017
Regenerative Medicine Earnings Scorecard - Q2/2017 - to date
35 companies, 1 interpreter!
Insight, foresight and recommendation
Opexa (OPXA) – OPXA’s P2b clinical trial of Tcelna® (imilecleucel-T) in secondary progressive multiple sclerosis (SPMS) (Abili-T trial) is nearing completion. Top line data is expected in early Q4/16. The final dose was administered to the last patient in 2/16 and approximately 98% of all patient visits have now been completed. The Abili-T clinical trial is being conducted at 35 clinical sites in the U.S. and Canada. Opexa has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Tcelna in SPMS. For Q1/16 OPXA reported a net loss of -$2.1 M, or -$0.31 per share, compared to a net loss of -$3.4 M or -$0.95 per share for Q1/15. RECOMMENDATION: BUY
buy
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors